Predicting hepatitis B return after stem cell transplant
Part of Blood & lymphatic, Infections clinical trials.
This study looks at people who had hepatitis B in the past (but are not currently infected) and are getting a stem cell transplant. The goal is to see if a simple model can predict whether the hepatitis B virus might come back, so doctors can monitor and treat it early.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are planning to have your first stem cell transplant using cells from a donor (allogeneic transplant).
- You have had hepatitis B in the past, but your current test shows you are not actively infected (HBsAg negative).
- Your blood test shows you have antibodies to the hepatitis B core (anti-HBc positive).
- You agree to follow the study's monitoring plan for hepatitis B after your transplant.
- You must not have other active liver infections (like hepatitis C, D, or HIV), liver cirrhosis, or liver cancer.
- You have not had a stem cell transplant before and have no history of organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
This study tracks patients who carry hepatitis B antibodies and are about to start immunosuppressive therapy (medications that weaken the immune system). Researchers want to understand when and how hepatitis B can reactivate in these patients and how to prevent it.
This study looks at the best time to give the hepatitis B vaccine after a stem cell transplant. It may help your body build protection against hepatitis B more effectively after your transplant.
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
This study looks at how often a common virus (CMV) becomes active again in children after a stem cell transplant from a donor. It will help doctors understand more about this risk and how to manage it.
This study looks at how well a new blood test detects cytomegalovirus (a common virus) in people who have had a stem cell transplant. The test may help doctors catch the virus early and treat it faster.
Hear when a new HSCT trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.